Skip to main content

The role of mycobiota-genotype association in inflammatory bowel diseases: a narrative review

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disease affecting various parts of the gastrointestinal tract. A majority of the current evidence points out the involvement of intestinal dysbiosis in the IBD pathogenesis. Recently, the association of intestinal fungal composition With IBD susceptibility and severity has been reported. These studies suggested gene polymorphisms in the front line of host defense against intestinal microorganisms are considered to play a role in IBD pathogenesis. The studies have also detected increased susceptibility to fungal infections in patients carrying IBD-related mutations. Therefore, a literature search was conducted in related databases to review articles addressing the mycobiota-genotype association in IBD.

Inflammatory bowel disease pathogenesis

Inflammatory bowel disease (IBD) is a chronic relapsing disease affecting various parts of the gastrointestinal tract and encompasses two common disorders: Crohn’s disease (CD) and Ulcerative Colitis (UC). IBD is a worldwide issue, especially in urban and westernized countries among young individuals [1], assumed to result from an improper and continuous inflammatory response to commensal microbes in a genetically susceptible host [2]. So far, the pathogenesis of the disease is considered to be a combination of genetic predisposition and environmental factors. The majority of current evidence emphasizes the involvement of intestinal dysbiosis in IBD pathogenesis [3]. While intestinal epithelial cells (IECs) are constantly exposed to microbial components; they are regarded not only as a structural but also a functional barrier in the front line of host defense against intestinal microorganisms. The functional alteration of these cells is hypothesized to be associated with IBD [4]. Bacteria as the predominant organisms of the gastrointestinal tract gained the greatest attention in IBD microbial studies [5,6,7]. Nonetheless, the association of intestinal fungal composition with mucosal inflammation in both CD and UC has recently become into consideration [8,9,10,11]. Of note, increased IBD flares were associated with increased global fungal load accompanied by alteration of certain fungal species in the microbiota [12,13,14].

To date, numerous gene polymorphisms are found to be connected to IBD susceptibility [15] and severity; for instance, an increased colitis severity was driven by activation of Leucine-rich repeat kinase 2 (LRRK2), an important enzyme that regulates innate immunity through nuclear factor kappa B (NF-κB) signaling pathway [16]. Some articles studied the association of specific intestinal bacterial microbiota with gene polymorphisms [17, 18]. However, few have focused on the role of fungal subsets in the intestine. The purpose of this study was to discuss the association of fungal flora with IBD and review the articles connecting the gene polymorphisms with intestinal mycobiota in IBD cases.

Anti-Saccharomyces cerevisiae antibody

The first sparks of fungi role in IBD pathogenesis flared by detecting elevated levels of anti-Saccharomyces cerevisiae mannan antibodies (ASCA) in the sera of IBD-affected patients since the early 90 s [19, 20]. A twin study in 2005 has detected ASCA in CD cases more frequently compared with healthy controls [21]. ASCA was also found commonly in CD patients with a positive family history of IBD [22] and even in unaffected relatives of CD patients [23]. ASCA was not only detected in answer to Saccharomyces antigens but also in response to Candida albicans or the presence of anti-β2 glycoprotein I antibodies in CD patients [24, 25]. Marrakchi et al. revealed a positive correlation of caspase recruitment domain-containing protein 15 (CARD15)/nucleotide-binding oligomerization domain-containing protein 2 (NOD2) gene mutation, an important intracellular pattern recognition receptor (PRR) that is expressed by dendritic cells (DCs), macrophages, and IECs [26], with ASCA expression in IBD-affected patients [27].

IBD affecting intestinal mycobiota

In addition to animal studies, some articles are conveying the alteration of intestinal mycobiome in human subjects with IBD. Ott et al. first described significantly higher fungal diversity in patients with CD in comparison with healthy controls, albeit no disease-specific fungal species were present in the CD and UC group [28]. Ever since, many studies have consistently shown an elevated abundance of Candida sp. in IBD fecal samples [29,30,31]. Lewis et al. have reported an increased amount of S. cerevisiae [29], whereas Hoarau et al. reported a reduction in intestinal S. cerevisiae abundance in IBD patients [31]. Another study in 2009 reported a significantly elevated C. albicans population obtained from fecal samples of CD patients (44%) and their healthy relatives (38%) compared to healthy controls [22]. Li et al. assessed 19 patients with active CD and 7 healthy individuals and discovered increased fecal fungal richness and diversity in C. albicans, Aspergillus clavatus, Cryptococcus neoformans, and a decrease in S. cerevisiae in CD patients. The diversity of the fecal fungal community was also positively correlated with serum C-reactive protein level and the CD activity index [13]. Another study in 2016, revealed a significant increase in global fungal load in both inflamed and non-inflamed mucosa compared with healthy subjects (HS). However, no significant differences in fungal diversity were observed between the groups [12].

Unlike most similar articles, Chehoud et al. demonstrated pediatric IBD to be associated with reduced fungal diversity in the host gut microbiota. Specific Candida taxa were also found to have increased abundance in the IBD samples [30]. An additional study with de-novo pediatric IBD cases revealed a shift from the Ascomycota-predominant mycobiota in HS to a different fungal spectrum with a predominance of Basidomycetes in patients with de-novo IBD without the conflicting impact of antibiotics or immunosuppression [32]. Later, another study investigated the possible fungal dysbiosis index in IBD; the fecal fungal composition of 235 patients with IBD and 38 HS showed an increased Basidiomycota-to-Ascomycota ratio that was dramatically higher in patients with IBD flares compared to patients in remission and HS [8]. There was also a negative correlation between the abundance of S. cerevisiae and C. albicans in fecal samples of IBD subjects, suggesting a competitive environment between these two species in the gut [8, 33]. The study also described a complex fungal-bacterial interaction in the fecal composition of subjects [8].

As opposed to Sokol and Mukhopadhya et al., Qiu and colleagues did not detect any significant difference in the abundance of Ascomycota, Basidiomycota, and the ratio of Ascomycota-to-Basidiomycota between the HS and UC patients. However, there was a prominent variation in the abundance of Aspergilli between the groups [11]. A recent report studied the cultivable intestinal mycobiota presented in feces obtained from 34 pediatric CD patients, 27 pediatric UC patients, and 32 healthy children. The authors observed increased load of S. cerevisiae and Candida sp. in IBD patients, which was in line with previous studies. Likewise, Di Paola et al. concluded that the presence of S. cerevisiae was associated with a favorable intestinal environment for beneficial bacterial genera, such as Faecalibacterium; whereas the absence of normal fungal flora or presence of unusual fungal species were conjugated with the presence of potential pathogenic bacteria that might lead to IBD [34]. The latest article by Nelson et al. reported an increased abundance of Candida sp. and a decreased Basidiomycota-to-Ascomycota ratio, in contrast to the previous literature, in CD cases [35]. Of note, the discrepancies between these studies might stem from different fungal extraction methods. In this regard, we provided additional information for these studies, including the fungal extraction method and the sample source, in Table 1.

Table 1 IBD affecting intestinal mycobiota in IBD patients

Innate immunity against fungi

Several genetic polymorphisms have been detected in IBD over the years [15, 36]. The connection between various genetic polymorphisms with bacterial species in IBD patients has been widely studied [37,38,39]. Increased susceptibility to systemic fungal complications, such as candidemia was linked to polymorphisms of Interleukin 10 (IL-10) (rs1800896) [40], Toll-like receptors 1 (TLR-1) (rs5743611, rs4833095, rs5743618) [41], Toll-like receptors 2 (TLR-2) [42], caspase recruitment domain-containing protein 9 (CARD9) (G72S,R373P,Q295X) [43, 44], Toll-like receptors 4 (TLR-4) (rs4986790,rs4986791) [45], and Dectin-1 [46] since 2006. Chronic mucocutaneous candidiasis is also related to Toll-like receptors 3 (TLR3) (rs3775291) and Dectin-1 mutations [46,47,48]. Gene polymorphisms targeting innate immunity may play an important role in IBD. Although studies aiming at the role of intestinal fungi pathogenesis in IBD are scarce, studies focusing on innate immune pathways against intestinal bacteria and their inflammatory consequences have successfully revealed important roles for innate immunity in IBD. Similarly, fungal recognition in the gut may be also regulated by innate immunity [49]. Four main types of innate immune receptors that can recognize fungi through fungal Pathogen-associated molecular patterns (PAMPs) are TLRs, C-type lectin receptors (CLRs), NOD-like receptors (NLRs), and galectin 3 on antigen-presenting cells [50]. The most studied class are the CLRs which include Dectin-1, Dectin-2, Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin receptor (DC-SIGN), Macrophage inducible Ca2+-dependent lectin receptor (MINCLE), and the Mannose Receptor (MR). Additionally, some CLRs can interact with TLRs to recognize fungi [51]. The β-glucan is the main PAMP that can be recognized by Dectin-1, although Dectin-1 can also recognize unidentified bacterial and endogenous ligands [52]. Dectin-2 has been recently shown to be the functional receptor for α-mannans and to be implicated in anti-bacterial immunity [53]. The α-mannose is also strongly suggested to be Mincle’s ligand, which has been implied in anti-mycobacterial immune activity [54]. The fractalkine receptor (CX3CR-1) expressed by intestinal-resident mononuclear phagocytes (MNPs), were also characterized to have a role in initiating immune responses against fungi [55]. Through fungal recognition, these pathways initiate the inflammatory cascade by predominantly driving the immune responses through spleen tyrosine kinase (SYK)-dependent, SYK-independent, and eventually NF-κB signaling pathway towards T helper 1 (TH1) and/or T helper 17 (TH17) immunophenotypes [56]. The brief signaling cascade leading to intestinal inflammation is available in Fig. 1.

Fig. 1
figure1

The cascade of innate immune response against intestinal fungi. Several fungal cell wall polysaccharides initiates immune responses, Dectin-1 binds β-glucans, dectin-2 binds α-mannans, and Mincle attaches the glycolipid trehalose-6,6-dimycolate (TDM), trehalose-6,6-dibehenate (TDB), and α-mannose residues. DC-SIGN binds N-linked mannans. Dectin-1, dectin-2, and mincle begin intracellular signaling through the SYK activation. RAF-1 as an SYK-independent activator of NF-κB pathway actuated by DC-SIGN and dectin-1. NF-κB pathway leads to TH1 and TH17 activations and subsequent cytokine production. CX3CR-1 is expressed by intestinal-resident mononuclear phagocytes (MNPs) and participate in fungal recognition

Intestinal mycobiota-genotype association

As Table 2 represents, here, we concentrated on articles reporting the mutations of innate immunity components and resulted in the gut mycobiome alteration. In a recent article, Limon et al. expressed that colonization of the colonic mucosa with Malassezia restricta, a commensal fungus typically found on the skin, might increase IBD severity in patients with CARD9S12N risk allele. They found out that the CARD9S12N variant induces a potent pro-inflammatory cytokine response against M. restricta in IBD [57]. By examining the SYK-CARD9 signaling axis and gut fungi, Malik et al. also demonstrated the decreased occurrence of Ascomycetes along with elevation of Saccharomycetes in Card9−/− mice. They implied that a normal inflammasome assembly in an unperturbed SYK-CARD9 signaling axis led to protection against colitis and colon cancer and also promoted T cell-mediated anti-tumorigenic responses; thereby indicating that a healthy gut mycobiota could prevent the development of IBD [58]. According to Lamas et al., the fungal microbiota of wild type and Card9−/− mice with induced-colitis mainly were members of the Ascomycota, Basidiomycota, and Zygomycota phyla. However, there were different measurements at the days 0, 7, and 12, and both groups reached a peak at day 7 that was higher in Card9−/− mice. On day 7, Card9−/− mice showed decreased fecal Ascomycota, increased fecal Basidiomycota, and Zygomycota communities [59].

Table 2 Intestinal mycobiota-genotype association in IBD

CX3CR-1 T280M (rs3732378) is a common polymorphism that has been previously detected in extra-intestinal inflammatory diseases [60, 61]. In 2018, Leonardi et al. described that CX3CR1 + MNPs not only modifies adaptive immune responses to intestinal fungi and controls the mycobiota during experimental colitis in animal models (without changing bacterial communities), but is also connected with a decrease in antifungal antibody responses in CD patients. They concluded that intestinal mycobiota and CX3CR1-dependent immune responses might provoke extra-intestinal manifestations of inflammatory diseases [62]. Elevated antifungal antibodies detected in patients with alcoholic liver disease, Graves’ disease, spondyloarthritis, and systemic lupus erythematous corroborate this hypothesis [63]. Finally, the article provided evidence for CX3CR1 + MNPs as a mediator between gut mycobiome and both local and systemic immunity [55].

A previous study was conducted by Sokol et al. to examine the correlation between host genotype and fungal microbiota in IBD patients. The ten most significant connections between IBD-associated fungi taxa and single-nucleotide polymorphisms (SNPs) were as follows: Malassezia sympodialis association with Dectin-1 (rs2078178, rs3901533), TLR1 (rs4833095, rs5743618), and Mincle (rs10841845); S. cerevisiae with CARD9 (rs10781499) and TLR3 (rs3775291); Ascomycota with DC-SIGN (rs2287886) and TLR1 (rs5743611); and Basidiomycota with TLR1 (rs5743611). They also provided evidence supporting the negative correlation of M. sympodialis fecal abundance with Dectin-1 SNP (rs2078178, ‘T’allele 12) in medically refractory UC; M. sympodialis was also decreased during the IBD flares in patients. Moreover, the IBD-associated CARD9 variation (rs10781499, ‘A’ allele 21) was inversely correlated with the fecal abundance of S. cerevisiae. Lastly, they reported a decrease in fungal biodiversity only in UC and CD patients without ileal involvement [8].

Wang et al. described the role of Dectin-3 (a family member of CLRs) in recognizing Candida. tropicalis in experimental-colitis pathogenesis for the first time. They observed that C. tropical increased the disease burden in Clec4d−/− mice during the induced colitis. Since the C-Type Lectin domain containing 4D (CLEC4D) is the encoding gene for Dectin-3, Clec4d−/− mice were more susceptible to induced colitis due to the activation of the NF-κB signaling pathway64.

The impact of NOD2 variants on the intestinal bacterial community in CD patients has previously been described [65]. Thus, Nelson et al. investigated the presence of NOD2 polymorphisms in CD patients and its relation with fecal fungal diversity but did not find any significant correlation between NOD2 variants and specific intestinal fungi community [35].

Dectin-1 is the most important fungal PRR expressed by innate immune cells, such as macrophages, dendritic cells, and neutrophils. C-Type Lectin domain containing 7A (CLEC7A) is the gene that encodes Dectin-1. Clec7−/− mice with induced colitis had increased proportions of opportunistic pathogenic fungi including Candida sp. and Trichosporon sp. along with a decreased frequency of nonpathogenic Saccharomyces. Iliev et al. identified a significant association between CLEC7A SNP (rs2078178) and patients suffering from medically refractory UC and delineated the role of Dectin-1 as a fungal receptor during severe forms of colitis [66]. Other gene polymorphisms were also described to influence Dectin-1-associated immunity in IBD [16, 67]. Among these genes, LRRK2 has also been described as the familial Parkinson’s disease genetic risk factor. Multiple variations in LRRK2 comprising N2081D, rs11175593 LRRK2/MUC19, and rs11564258 LRRK2/MUC19 were associated with IBD as well [68]. Takagawa et al. suggested an increase in severity of colitis, mediated by increased Dectin-1–induced immunity, in (rs11564258) LRRK2/MUC19 polymorphism carriers [16]. Noteworthily, this variance (rs11564258) had the second-highest odds ratio in IBD patients of the European population [69]. Further studies are required to identify the intestinal mycobiota in the patients carrying this mutation.

Conclusion

In summary, the role of intestinal fungal mycobiota in IBD pathogenesis and severity index have been quite underrated. This review emphasizes that a majority of IBD-affected patients had increased diversity and richness of intestinal mycobiome, higher abundance of C. albicans and Basidiomycota-to-Ascomycota ratio, and a decreased proportion of S. cerevisiae despite a few contradictory results in other studies.

It is widely known that innate immunity takes part in intestinal fungal recognition and mutations in innate immunity mediators are linked to IBD pathogenesis. Even so, few articles aimed to examine the connection between gene polymorphisms and intestinal fungal dysbiosis in IBD.

Although DSS-induced colitis is a well-established experimental murine model with much resemblance to human IBD [70], we were able to find only three non-murine studies containing mycobiota-genotype data related to IBD patients. Additional evidence is needed to determine whether different gene polymorphisms can alter intestinal mycobiome or whether this information would be of use in providing novel insight into IBD pathogenesis. Therefore, our purpose was to highlight the importance of the matter and draw attention to this underappreciated aspect of IBD-associated research.

Abbreviations

IBD:

Inflammatory bowel disease

CD:

Crohn’s disease

UC:

Ulcerative Colitis

IECs:

Intestinal epithelial cells

LRRK2:

Leucine-rich repeat kinase 2

ASCA:

Anti-Saccharomyces cerevisiae antibody

CARD15:

Caspase recruitment domain-containing protein 15

NOD2:

Nucleotide-binding oligomerization domain-containing protein 2

PRR:

Pattern recognition receptor

DCs:

Dendritic cells

IL-10:

Interleukin 10

TLR-1:

Toll-like receptors 1

TLR-2:

Toll-like receptors 2

CARD9:

Caspase recruitment domain-containing protein 9

TLR-4:

Toll-like receptors 4

PAMPs:

Pathogen-associated molecular patterns

CLRs:

C-type lectin receptors

NLRs:

NOD-like receptors

DC-SIGN:

Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin receptor

MINCLE:

Macrophage inducible Ca2+-dependent lectin receptor

MR:

Mannose Receptor

MNPs:

Mononuclear phagocytes

SYK:

Spleen tyrosine kinase

SNPs:

Single-nucleotide polymorphisms

TLR3:

Toll-like receptors 3

CLEC4D:

C-Type Lectin domain containing 4D

CLEC7A:

C-Type Lectin domain containing 7A

TH1:

T helper 1

TH17:

T helper 17

IL-1:

Interleukin 1

IL-17:

Interleukin 17

References

  1. 1.

    Zuo T, Kamm MA, Colombel JF, Ng SC. Urbanization and the gut microbiota in health and inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2018;15:440–52.

    PubMed  Article  Google Scholar 

  2. 2.

    Endo K, Shiga H, Kinouchi Y, Shimosegawa T. Inflammatory bowel disease: IBD. Rinsho Byori. 2009;57:527–32.

    CAS  PubMed  Google Scholar 

  3. 3.

    Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–17.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology. 2017;152:327-339.e324.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11:1–10.

    PubMed  Article  Google Scholar 

  6. 6.

    Spalinger MR, Schmidt TS, Schwarzfischer M, Hering L, Atrott K, Lang S, Gottier C, Geirnaert A, Lacroix C, Dai X, et al. Protein tyrosine phosphatase non-receptor type 22 modulates colitis in a microbiota-dependent manner. J Clin Invest. 2019;129:2527–41.

    PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Yu LC. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis. J Biomed Sci. 2018;25:79.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I, et al. Fungal microbiota dysbiosis in IBD. Gut. 2017;66:1039–48.

    CAS  Article  Google Scholar 

  9. 9.

    Leonardi I, Paramsothy S, Doron I, Semon A, Kaakoush NO, Clemente JC, Faith JJ, Borody TJ, Mitchell HM, Colombel JF, et al. Fungal trans-kingdom dynamics linked to responsiveness to fecal microbiota transplantation (FMT) therapy in ulcerative Colitis. Cell Host Microbe. 2020;27:823-829.e823.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Zhu F, Feng D, Ding C, Zhang T, Chen J, Yu Z, Zhao L, Xu Y, Zhu W, Gong J. Fungal dysbiosis aggravates pouchitis in a rat model of ileal pouch anal anastomosis. Inflamm Bowel Dis. 2020;26:1831.

    PubMed  Article  Google Scholar 

  11. 11.

    Qiu X, Ma J, Jiao C, Mao X, Zhao X, Lu M, Wang K, Zhang H. Alterations in the mucosa-associated fungal microbiota in patients with ulcerative colitis. Oncotarget. 2017;8:107577–88.

    PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Liguori G, Lamas B, Richard ML, Brandi G, da Costa G, Hoffmann TW, Di Simone MP, Calabrese C, Poggioli G, Langella P, et al. Fungal dysbiosis in mucosa-associated microbiota of Crohn’s disease patients. J Crohns Colitis. 2016;10:296–305.

    PubMed  Article  Google Scholar 

  13. 13.

    Li Q, Wang C, Tang C, He Q, Li N, Li J. Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in crohn’s disease. J Clin Gastroenterol. 2014;48:513–23.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Chiaro TR, Soto R, Stephens WZ, Kubinak JL, Petersen C, Gogokhia L, Bell R, Delgado JC, Cox J, Voth W, et al. A member of the gut mycobiota modulates host purine metabolism exacerbating colitis in mice. Sci Transl Med. 2017. https://doi.org/10.1126/scitranslmed.aaf9044.

    Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Bank S, Skytt Andersen P, Burisch J, Pedersen N, Roug S, Galsgaard J, Turino YS, Brodersen JB, Rashid S, Rasmussen KB, et al. Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort. PLoS ONE. 2014;9:e98815.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  16. 16.

    Takagawa T, Kitani A, Fuss I, Levine B, Brant SR, Peter I, Tajima M, Nakamura S, Strober W. An increase in LRRK2 suppresses autophagy and enhances Dectin-1-induced immunity in a mouse model of colitis. Sci Transl Med. 2018;10:eaan8162. https://doi.org/10.1126/scitranslmed.aan8162

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Cousins DV, Whittington R, Marsh I, Masters A, Evans RJ, Kluver P. Mycobacteria distenct from Mycobacterium avium subsp. paratuberculosis isolated from the faeces of ruminants possess IS900-like sequences detectable IS900 polymerase chain reaction: implications for diagnosis. Mol Cell Probes. 1999;13:431–42.

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Andoh A, Tsujikawa T, Sasaki M, Mitsuyama K, Suzuki Y, Matsui T, Matsumoto T, Benno Y, Fujiyama Y. Faecal microbiota profile of Crohn’s disease determined by terminal restriction fragment length polymorphism analysis. Aliment Pharmacol Ther. 2009;29:75–82.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    McKenzie H, Main J, Pennington CR, Parratt D. Antibody to selected strains of Saccharomyces cerevisiae (baker’s and brewer’s yeast) and Candida albicans in Crohn’s disease. Gut. 1990;31:536–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  20. 20.

    Vermeire S, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, Groenen P, Vlietinck R, Rutgeerts P. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology. 2001;120:827–33.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Halfvarson J, Standaert-Vitse A, Järnerot G, Sendid B, Jouault T, Bodin L, Duhamel A, Colombel JF, Tysk C, Poulain D. Anti-saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut. 2005;54:1237–43.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Standaert-Vitse A, Sendid B, Joossens M, François N, Vandewalle-El Khoury P, Branche J, Van Kruiningen H, Jouault T, Rutgeerts P, Gower-Rousseau C, et al. Candida albicans colonization and ASCA in familial Crohn’s disease. Am J Gastroenterol. 2009;104:1745–53.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Sutton CL, Yang H, Li Z, Rotter JI, Targan SR, Braun J. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn’s disease. Gut. 2000;46:58–63.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Standaert-Vitse A, Jouault T, Vandewalle P, Mille C, Seddik M, Sendid B, Mallet JM, Colombel JF, Poulain D. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn’s disease. Gastroenterology. 2006;130:1764–75.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Mankaï A, Layouni S, Ghedira I. Anti saccharomyces cerevisiae antibodies in patients with anti-β2 glycoprotein I antibodies. J Clin Lab Anal. 2016;30:818–22.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  26. 26.

    Ramanan D, Tang MS, Bowcutt R, Loke P, Cadwell K. Bacterial sensor Nod2 prevents inflammation of the small intestine by restricting the expansion of the commensal Bacteroides vulgatus. Immunity. 2014;41:311–24.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    Marrakchi R, Bougatef K, Moussa A, Ouerhani S, Khodjet-el-Khil H, Messai Y, Mestiri O, Najar T, Benammar-Elgaaeid A. 3020insC insertion in NOD2/CARD15 gene, a prevalent variant associated with anti-Saccharomyces cerevisiae antibodies and ileal location of Crohn’s disease in Tunisian population. Inflamm Res. 2009;58:218–23.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Ott SJ, Kühbacher T, Musfeldt M, Rosenstiel P, Hellmig S, Rehman A, Drews O, Weichert W, Timmis KN, Schreiber S. Fungi and inflammatory bowel diseases: alterations of composition and diversity. Scand J Gastroenterol. 2008;43:831–41.

    CAS  PubMed  Article  Google Scholar 

  29. 29.

    Lewis JD, Chen EZ, Baldassano RN, Otley AR, Griffiths AM, Lee D, Bittinger K, Bailey A, Friedman ES, Hoffmann C, et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn’s Disease. Cell Host Microbe. 2015;18:489–500.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Chehoud C, Albenberg LG, Judge C, Hoffmann C, Grunberg S, Bittinger K, Baldassano RN, Lewis JD, Bushman FD, Wu GD. Fungal signature in the gut microbiota of pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1948–56.

    PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Hoarau G, Mukherjee PK, Gower-Rousseau C, Hager C, Chandra J, Retuerto MA, Neut C, Vermeire S, Clemente J, Colombel JF, et al. Bacteriome and mycobiome interactions underscore microbial dysbiosis in familial Crohn’s disease. MBio. 2016. https://doi.org/10.1128/mBio.01250-16.

    Article  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Mukhopadhya I, Hansen R, Meharg C, Thomson JM, Russell RK, Berry SH, El-Omar EM, Hold GL. The fungal microbiota of de-novo paediatric inflammatory bowel disease. Microbes Infect. 2015;17:304–10.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Lam S, Zuo T, Ho M, Chan F, Chan P, Ng S. Fungal alterations in inflammatory bowel diseases. Alimentary Pharmacol Therapeutics. 2019;50:1159.

    Article  Google Scholar 

  34. 34.

    Di Paola M, Rizzetto L, Stefanini I, Vitali F, Massi-Benedetti C, Tocci N, Romani L, Ramazzotti M, Lionetti P, De Filippo C, Cavalieri D. Comparative immunophenotyping of Saccharomyces cerevisiae and Candida spp. strains from Crohn’s disease patients and their interactions with the gut microbiome. J Transl Autoimmunity. 2020;3:10036.

    Article  Google Scholar 

  35. 35.

    Nelson A, Stewart CJ, Kennedy NA, Lodge JK, Tremelling M, Probert CS, Parkes M, Mansfield JC, Smith DL, Hold GL, et al. The impact of NOD2 Genetic variants on the gut mycobiota in Crohn’s disease patients in remission and individuals without gastrointestinal inflammation. J Crohns Colitis. 2020. https://doi.org/10.1093/ecco-jcc/jjaa220.

    Article  Google Scholar 

  36. 36.

    Choteau L, Vasseur F, Lepretre F, Figeac M, Gower-Rousseau C, Dubuquoy L, Poulain D, Colombel JF, Sendid B, Jawhara S. Polymorphisms in the mannose-binding lectin gene are associated with defective mannose-binding lectin functional activity in Crohn’s disease patients. Sci Rep. 2016;6:29636.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. 37.

    Turpin W, Bedrani L, Espin-Garcia O, Xu W, Silverberg MS, Smith MI, Guttman DS, Griffiths A, Moayyedi P, Panaccione R, et al. FUT2 genotype and secretory status are not associated with fecal microbial composition and inferred function in healthy subjects. Gut Microbes. 2018;9:357–68.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Zakrzewski M, Simms LA, Brown A, Appleyard M, Irwin J, Waddell N, Radford-Smith GL. IL23R-protective coding variant promotes beneficial bacteria and diversity in the ileal microbiome in healthy individuals without inflammatory bowel disease. J Crohns Colitis. 2019;13:451–61.

    PubMed  Article  Google Scholar 

  39. 39.

    Yilmaz B, Spalinger MR, Biedermann L, Franc Y, Fournier N, Rossel J-B, Juillerat P, Rogler G, Macpherson AJ, Scharl M. The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients. PLoS ONE. 2018;13:e0199664–e0199664.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  40. 40.

    Johnson MD, Plantinga TS, van de Vosse E, Velez Edwards DR, Smith PB, Alexander BD, Yang JC, Kremer D, Laird GM, Oosting M, et al. Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. Clin Infect Dis. 2012;54:502–10.

    CAS  PubMed  Article  Google Scholar 

  41. 41.

    Plantinga TS, Johnson MD, Scott WK, van de Vosse E, Velez Edwards DR, Smith PB, Alexander BD, Yang JC, Kremer D, Laird GM, et al. Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J Infect Dis. 2012;205:934–43.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    Netea MG, Van Der Graaf CA, Vonk AG, Verschueren I, Van Der Meer JW, Kullberg BJ. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis. 2002;185:1483–9.

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Glocker EO, Hennigs A, Nabavi M, Schäffer AA, Woellner C, Salzer U, Pfeifer D, Veelken H, Warnatz K, Tahami F, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med. 2009;361:1727–35.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Drewniak A, Gazendam RP, Tool AT, van Houdt M, Jansen MH, van Hamme JL, van Leeuwen EM, Roos D, Scalais E, de Beaufort C, et al. Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. Blood. 2013;121:2385–92.

    CAS  PubMed  Article  Google Scholar 

  45. 45.

    Van der Graaf CA, Netea MG, Morré SA, Den Heijer M, Verweij PE, Van der Meer JW, Kullberg BJ. Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw. 2006;17:29–34.

    PubMed  Google Scholar 

  46. 46.

    Tam JM, Reedy JL, Lukason DP, Kuna SG, Acharya M, Khan NS, Negoro PE, Xu S, Ward RA, Feldman MB, et al. Tetraspanin CD82 organizes Dectin-1 into signaling domains to mediate cellular responses to Candida albicans. J Immunol. 2019;202:3256–66.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  47. 47.

    Nahum A, Dadi H, Bates A, Roifman CM. The biological significance of TLR3 variant, L412F, in conferring susceptibility to cutaneous candidiasis, CMV and autoimmunity. Autoimmun Rev. 2012;11:341–7.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Plantinga TS, van der Velden WJ, Ferwerda B, van Spriel AB, Adema G, Feuth T, Donnelly JP, Brown GD, Kullberg BJ, Blijlevens NM, Netea MG. Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2009;49:724–32.

    CAS  PubMed  Article  Google Scholar 

  49. 49.

    Underhill D, Braun J. Current understanding of fungal microflora in inflammatory bowel disease pathogenesis. Inflamm Bowel Dis. 2008;14:1147–53.

    PubMed  PubMed Central  Article  Google Scholar 

  50. 50.

    Bourgeois C, Kuchler K. Fungal pathogens—a sweet and sour treat for toll-like receptors. Front Cell Infect Microbiol. 2012;2:142.

    PubMed  PubMed Central  Article  Google Scholar 

  51. 51.

    Vautier S, MacCallum DM, Brown GD. C-type lectin receptors and cytokines in fungal immunity. Cytokine. 2012;58:89–99.

    CAS  PubMed  Article  Google Scholar 

  52. 52.

    Taylor PR, Tsoni SV, Willment JA, Dennehy KM, Rosas M, Findon H, Haynes K, Steele C, Botto M, Gordon S, Brown GD. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol. 2007;8:31–8.

    CAS  PubMed  Article  Google Scholar 

  53. 53.

    Saijo S, Ikeda S, Yamabe K, Kakuta S, Ishigame H, Akitsu A, Fujikado N, Kusaka T, Kubo S, Chung SH, et al. Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity. 2010;32:681–91.

    CAS  PubMed  Article  Google Scholar 

  54. 54.

    Yamasaki S, Matsumoto M, Takeuchi O, Matsuzawa T, Ishikawa E, Sakuma M, Tateno H, Uno J, Hirabayashi J, Mikami Y, et al. C-type lectin Mincle is an activating receptor for pathogenic fungus, Malassezia. Proc Natl Acad Sci U S A. 2009;106:1897–902.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    Leonardi I, Li X, Semon A, Li D, Doron I, Putzel G, Bar A, Prieto D, Rescigno M, McGovern DPB, et al. CX3CR1(+) mononuclear phagocytes control immunity to intestinal fungi. Science. 2018;359:232–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  56. 56.

    Richard ML, Sokol H. The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. 2019;16:331–45.

    PubMed  Google Scholar 

  57. 57.

    Limon JJ, Tang J, Li D, Wolf AJ, Michelsen KS, Funari V, Gargus M, Nguyen C, Sharma P, Maymi VI, et al. Malassezia is associated with Crohn’s disease and exacerbates colitis in mouse models. Cell Host Microbe. 2019;25:377-388.e376.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Malik A, Sharma D, Malireddi RKS, Guy CS, Chang TC, Olsen SR, Neale G, Vogel P, Kanneganti TD. SYK-CARD9 signaling axis promotes gut fungi-mediated inflammasome activation to restrict colitis and colon cancer. Immunity. 2018;49:515-530.e515.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  59. 59.

    Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, Bridonneau C, Jegou S, Hoffmann TW, Natividad JM, et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 2016;22:598–605.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  60. 60.

    Moatti D, Faure S, Fumeron F, Amara Mel W, Seknadji P, McDermott DH, Debré P, Aumont MC, Murphy PM, de Prost D, Combadière C. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 2001;97:1925–8.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Wan W, Murphy PM. Regulation of atherogenesis by chemokines and chemokine receptors. Arch Immunol Ther Exp. 2013;61:1–14.

    CAS  Article  Google Scholar 

  62. 62.

    Leonardi I, Li X, Semon A, Li D, Doron I, Putzel G, Bar A, Prieto D, Rescigno M, McGovern DPB, et al. CX3CR1+, mononuclear phagocytes control immunity to intestinal fungi. Science. 2018;359:232–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  63. 63.

    Li XV, Leonardi I, Iliev ID. Gut mycobiota in immunity and inflammatory disease. Immunity. 2019;50:1365–79.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  64. 64.

    Wang T, Pan D, Zhou Z, You Y, Jiang C, Zhao X, Lin X. Dectin-3 deficiency promotes colitis development due to impaired antifungal innate immune responses in the gut. PLoS Pathog. 2016;12:e1005662.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  65. 65.

    Kennedy NA, Lamb CA, Berry SH, Walker AW, Mansfield J, Parkes M, Simpkins R, Tremelling M, Nutland S, Parkhill J, et al. The impact of NOD2 variants on fecal microbiota in Crohn’s disease and controls without gastrointestinal disease. Inflamm Bowel Dis. 2018;24:583–92.

    PubMed  PubMed Central  Article  Google Scholar 

  66. 66.

    Iliev ID, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP, Brown J, Becker CA, Fleshner PR, Dubinsky M, et al. Interactions between commensal fungi and the C-type lectin receptor dectin-1 influence colitis. Science. 2012;336:1314–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  67. 67.

    de Vries HS, Plantinga TS, van Krieken JH, Stienstra R, van Bodegraven AA, Festen EA, Weersma RK, Crusius JB, Linskens RK, Joosten LA, et al. Genetic association analysis of the functional c.714T>G polymorphism and mucosal expression of dectin-1 in inflammatory bowel disease. PLoS ONE. 2009;4:e7818.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  68. 68.

    Rastegar AD, Dzamko N. Leucine rich repeat kinase 2 and innate immunity. Front Neurosci. 2020. https://doi.org/10.3389/fnins.2020.00193.

    Article  PubMed  PubMed Central  Google Scholar 

  69. 69.

    Franke A, McGovern DPB, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42:1118–25.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  70. 70.

    Pakravan N, Kermanian F, Mahmoudi E. Filtered Kombucha tea ameliorates the leaky gut syndrome in young and old mice model of colitis. Iran J Basic Med Sci. 2020;22:1158.

    Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Affiliations

Authors

Contributions

All the authors read and approved the final manuscript.

Corresponding author

Correspondence to Niusha Sharifinejad.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mahmoudi, E., Mozhgani, SH. & Sharifinejad, N. The role of mycobiota-genotype association in inflammatory bowel diseases: a narrative review. Gut Pathog 13, 31 (2021). https://doi.org/10.1186/s13099-021-00426-4

Download citation

Keywords

  • Inflammatory bowel disease
  • IBD
  • Fungal microbiota
  • Intestinal mycobiota
  • Single nucleotide polymorphisms
  • SNPs